# RedHill Biopharma Ltd.: Form 20-F for the period ended Dec 31, 2024

- Company: [RedHill Biopharma Ltd.](/companies/rdhl.md) (CIK 1553846)
- Form: 20-F
- Filed: 2025-04-10
- Accepted by EDGAR: Apr 10, 2025, 07:36 ET
- Period: 2024-12-31
- Accession: 0001558370-25-004648
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1553846/000155837025004648/rdhl-20241231x20f.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1553846/000155837025004648/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2024-12-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 12 months, 2024-01-01 to 2024-12-31 | $8.0m | ifrs-full:Revenue |
| Cost of revenue | 12 months, 2024-01-01 to 2024-12-31 | $3.2m | ifrs-full:CostOfSales |
| Gross profit | 12 months, 2024-01-01 to 2024-12-31 | $4.9m | ifrs-full:GrossProfit |
| Operating income | 12 months, 2024-01-01 to 2024-12-31 | −$14.6m | ifrs-full:ProfitLossFromOperatingActivities |
| Net income | 12 months, 2024-01-01 to 2024-12-31 | −$8.3m | ifrs-full:ProfitLoss |
| Diluted EPS | 12 months, 2024-01-01 to 2024-12-31 | $0.00 | ifrs-full:DilutedEarningsLossPerShare |
| Basic EPS | 12 months, 2024-01-01 to 2024-12-31 | $0.00 | ifrs-full:BasicEarningsLossPerShare |
| Operating cash flow | 12 months, 2024-01-01 to 2024-12-31 | −$9.4m | ifrs-full:CashFlowsFromUsedInOperatingActivities |
| Capital expenditure | 12 months, 2024-01-01 to 2024-12-31 | $9.0k | ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities |
| Cash and equivalents | at 2024-12-31 | $4.6m | ifrs-full:CashAndCashEquivalents |
| Current assets | at 2024-12-31 | $11.9m | ifrs-full:CurrentAssets |
| Total assets | at 2024-12-31 | $18.0m | ifrs-full:Assets |
| Current liabilities | at 2024-12-31 | $22.2m | ifrs-full:CurrentLiabilities |
| Total liabilities | at 2024-12-31 | $22.7m | ifrs-full:Liabilities |
| Shareholders' equity | at 2024-12-31 | −$4.7m | ifrs-full:Equity |
| Shares outstanding | at 2024-12-31 | 12,899,831,000 shares | dei:EntityCommonStockSharesOutstanding |

## Sections

Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. https://www.sec.gov/Archives/edgar/data/1553846/000155837025004648/rdhl-20241231x20f.htm

Filed Apr 10, 2025.
Source: SEC EDGAR, the filing index for accession 0001558370-25-004648. Last ingested by Listed: Nov 2, 2026, 07:05 ET. No prices; not investment advice.